Your browser is no longer supported. Please, upgrade your browser.
CRTX [NASD]
Cortexyme, Inc.
Index- P/E- EPS (ttm)-2.81 Insider Own1.20% Shs Outstand29.55M Perf Week-5.28%
Market Cap1.09B Forward P/E- EPS next Y-4.25 Insider Trans-7.87% Shs Float19.35M Perf Month3.34%
Income-82.80M PEG- EPS next Q-0.75 Inst Own62.00% Short Float18.90% Perf Quarter-15.39%
Sales- P/S- EPS this Y-35.60% Inst Trans4.36% Short Ratio12.40 Perf Half Y-20.30%
Book/sh5.29 P/B7.01 EPS next Y-43.10% ROA-42.00% Target Price- Perf Year-21.31%
Cash/sh5.03 P/C7.38 EPS next 5Y18.30% ROE-45.80% 52W Range26.66 - 58.99 Perf YTD33.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.11% Beta-
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low39.15% ATR2.61
Employees37 Current Ratio8.40 Sales Q/Q- Oper. Margin- RSI (14)49.92 Volatility6.17% 7.52%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.50% Profit Margin- Rel Volume0.38 Prev Close36.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume295.05K Price37.10
Recom2.70 SMA20-0.43% SMA501.30% SMA200-9.84% Volume111,614 Change1.15%
Apr-26-21Resumed Credit Suisse Underperform $14
Feb-17-21Downgrade Jefferies Buy → Hold $59 → $34
Dec-11-20Initiated Citigroup Sell $20
Jun-24-20Initiated H.C. Wainwright Buy $76
Jun-02-20Initiated Jefferies Buy $59
Jun-03-19Initiated JMP Securities Mkt Outperform $53
Jun-03-19Initiated Credit Suisse Underperform $14
Jun-03-19Initiated Canaccord Genuity Buy $42
Jun-03-19Initiated BofA/Merrill Neutral $28
May-04-21 08:00AM  
Mar-25-21 08:00AM  
Mar-21-21 09:52PM  
Mar-18-21 08:01PM  
Mar-16-21 10:00PM  
Mar-12-21 06:15AM  
Mar-10-21 08:00AM  
Mar-09-21 10:45PM  
Mar-08-21 08:00AM  
Mar-07-21 05:53PM  
Mar-03-21 03:00AM  
Feb-22-21 01:10PM  
Feb-20-21 07:00PM  
Feb-18-21 09:47PM  
04:45PM  
Feb-17-21 11:38AM  
Feb-16-21 08:52AM  
Feb-15-21 09:13PM  
Feb-10-21 04:06PM  
Feb-08-21 08:22AM  
12:26AM  
Feb-02-21 07:32PM  
Jan-26-21 08:00AM  
Jan-06-21 08:49AM  
Dec-07-20 12:49AM  
Dec-04-20 07:43AM  
07:00AM  
Dec-01-20 08:40AM  
Nov-27-20 10:27AM  
Nov-20-20 10:45AM  
Nov-12-20 04:30PM  
Nov-10-20 07:12AM  
Nov-05-20 08:00AM  
Oct-19-20 08:00AM  
Sep-24-20 08:00AM  
Sep-09-20 08:00AM  
Aug-27-20 08:00AM  
Aug-18-20 09:21AM  
Aug-17-20 08:00AM  
Aug-14-20 08:00AM  
Aug-12-20 08:11AM  
08:10AM  
Aug-06-20 04:05PM  
Jul-29-20 08:00AM  
Jul-28-20 06:09PM  
Jul-22-20 08:00AM  
Jun-14-20 07:00AM  
Jun-12-20 04:27PM  
Jun-09-20 08:00AM  
Jun-02-20 09:44AM  
May-27-20 08:00AM  
May-14-20 11:44AM  
May-12-20 04:05PM  
May-07-20 08:00AM  
May-06-20 08:30AM  
Apr-30-20 04:05PM  
Apr-06-20 08:30AM  
Apr-02-20 08:00AM  
Mar-17-20 08:00AM  
Mar-16-20 08:00AM  
Feb-13-20 08:00AM  
Feb-10-20 04:05PM  
Feb-05-20 09:00PM  
Jan-30-20 08:18AM  
Jan-13-20 08:00AM  
Jan-08-20 04:05PM  
Jan-05-20 08:14AM  
Jan-03-20 10:15AM  
Dec-22-19 06:38PM  
Dec-13-19 11:16AM  
Dec-11-19 06:32PM  
Dec-09-19 08:44AM  
Dec-07-19 01:00PM  
Dec-02-19 01:56PM  
Nov-26-19 04:05PM  
Nov-12-19 04:05PM  
Nov-08-19 10:34AM  
Nov-07-19 08:18AM  
Nov-01-19 08:00AM  
Oct-09-19 09:14AM  
Oct-07-19 09:36AM  
Sep-26-19 08:00AM  
Sep-23-19 10:54AM  
Aug-08-19 11:45AM  
Jul-31-19 04:05PM  
Jul-17-19 11:00AM  
Jul-10-19 08:00AM  
Jul-05-19 10:05AM  
Jul-01-19 02:08PM  
Jun-26-19 12:31PM  
Jun-19-19 08:00AM  
Jun-10-19 08:00AM  
May-08-19 07:22PM  
May-04-19 05:25PM  
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lamond DavidDirectorMar 24Buy33.7750,0001,688,5001,847,109Mar 24 09:06 PM
Lynch CaseyChief Executive OfficerMar 22Sale35.5930,0001,067,6111,008,774Mar 23 07:06 PM
Lamond DavidDirectorMar 04Buy35.3450,0001,767,0571,797,109Mar 05 05:54 PM
Lynch CaseyChief Executive OfficerFeb 03Sale43.0320,000860,5301,038,774Feb 03 07:45 PM
Lynch CaseyChief Executive OfficerFeb 02Sale36.2120,000724,1021,058,774Feb 03 07:45 PM
Lynch CaseyChief Executive OfficerFeb 01Sale36.2520,000724,9681,078,774Feb 03 07:45 PM
Holsinger LeslieExecutive Vice PresidentDec 14Option Exercise0.2740,00010,80043,500Dec 15 07:17 PM
Holsinger LeslieExecutive Vice PresidentDec 14Sale30.8140,0001,232,5281,800Dec 15 07:17 PM
Holsinger LeslieExecutive Vice PresidentDec 10Option Exercise0.273,5009453,500Dec 14 05:16 PM
EPIQ Capital Group, LLCIA/Managing Member of 10% OwneJun 12Buy44.062,440107,5062,860,967Jun 15 06:55 PM
EPIQ Capital Group, LLCIA/Managing Member of 10% OwneJun 11Buy44.326,600292,5122,858,527Jun 15 06:55 PM
Lamond DavidDirectorJun 04Buy43.2749,1252,125,7951,747,109Jun 08 06:47 PM
PFIZER INC10% OwnerJun 03Sale40.18370,00014,866,6002,879,973Jun 04 04:25 PM
Detke Michael J.Chief Medical OfficerMay 27Option Exercise6.915,51538,10928,261May 29 04:48 PM
EPIQ Capital Group, LLCIA/Managing Member of 10% OwneMay 22Buy55.902,085116,5522,851,927May 22 06:03 PM
EPIQ Capital Group, LLCIA/Managing Member of 10% OwneMay 21Buy55.8052029,0162,849,842May 22 06:03 PM
EPIQ Capital Group, LLCIA/Managing Member of 10% OwneMay 20Buy57.956,085352,6052,849,322May 22 06:03 PM
Lamond DavidDirectorMay 19Buy56.2439,2002,204,6831,697,984May 19 06:41 PM
Lamond DavidDirectorMay 15Buy48.935,448266,5691,658,784May 19 06:41 PM